Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.3289 | 0.3289 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.4591 | 0.4591 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4591 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4591 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.1767 | 0.1767 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4591 | 1 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.4591 | 1 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.3289 | 0.3289 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.3289 | 0.3289 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.1767 | 0.1767 |
Brugia malayi | RNA binding protein | 0.0076 | 0.4591 | 0.4591 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.4591 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.1767 | 0.3848 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.4591 | 0.4591 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.3289 | 0.3289 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.4591 | 0.4591 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.4591 | 0.4591 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.4591 | 0.4591 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4591 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.4591 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS Assay for Activators of ClpP. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.